Results 41 to 50 of about 1,220,899 (350)

Antibiotics with Interleukin-15 inhibition reduces joint inflammation and bone erosions but not cartilage destruction in Staphylococcus aureus-induced arthritis [PDF]

open access: yes, 2018
Background: Staphylococcus aureus-induced arthritis causes rapid joint destruction, often leading to disabling joint damage despite antibiotics. We have previously shown that IL-15 inhibition without antibiotics is beneficial in S.
Bergmann, Berglind   +7 more
core   +1 more source

Seronegative Bilateral Symmetrical Inflammatory Polyarthritis: Think Twice Before Starting Immunosuppression

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2018
The most common cause of bilateral symmetrical polyarthritis in the small joints is rheumatoid arthritis. However, if seronegative arthritis is involved, it could be the case that other underlying causes need to be diagnosed.
Omar Alsaed   +3 more
doaj   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

open access: yes, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta   +11 more
core   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

open access: yes, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P.   +4 more
core   +2 more sources

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

open access: yesArthritis Research & Therapy, 2023
Background Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS programs. We report the 1-year efficacy and safety in patients with AS
Xenofon Baraliakos   +10 more
doaj   +1 more source

Role of shear wave elastography of synovium to differentiate rheumatoid and tubercular arthritis

open access: yesJournal of Medical Ultrasound, 2022
Background: Synovitis is the underlying pathology in various arthritis, and sometimes, it is difficult to differentiate various arthritis clinically or even by imaging.
Karamvir Chandel   +5 more
doaj   +1 more source

Pathogenesis and modern methods for treatment of hip infectious arthritis: a review [PDF]

open access: yesTravmatologiâ i Ortopediâ Rossii
Background. One of the little-studied but long-known problems is determining the optimal treatment regimen for patients with infectious arthritis of the hip joint.
Denis I. Astakhov, Vasily A. Artyukh
doaj   +1 more source

Microbial profile of the appendix niche in acute appendicitis: a novel sampling approach

open access: yesFEBS Open Bio, EarlyView.
This study utilized a novel sampling method, ERAT (i.e. endoscopic retrograde appendicitis treatment)‐guided lumen aspiration, to obtain samples from the appendix, and shotgun metagenomic sequencing was performed for in situ characterization of the appendix microbiome in patients with acute appendicitis.
Huimin Ma   +10 more
wiley   +1 more source

Circulating anti-galectin-1 antibodies are associated with the severity of ocular disease in autoimmune and infectious uveitis [PDF]

open access: yes, 2006
Galectin (Gal)-1, an endogenous lectin found at sites of immune privilege, plays a critical role in the regulation of the immune response. Therapeutic administration of Gal-1 or its genetic delivery suppresses chronic inflammation in experimental models ...
Bianco, German Ariel   +6 more
core   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy